Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician

被引：0
作者：
Tiago L. L. Leiria
Renato D. Lopes
Judson B. Williams
Jason N. Katz
Renato A. K. Kalil
John H. Alexander
机构：
[1] Instituto de Cardiologia do Rio Grande do Sul/Fundação Universitária de Cardiologia,Duke Clinical Research Institute, Division of Cardiology, Department of Medicine
[2] Duke University Medical Center,Duke Clinical Research Institute, Division of Cardiovascular and Thoracic Surgery, Department of Surgery
[3] Duke University Medical Center,Division of Cardiology & Division of Pulmonary/Critical Care Medicine
[4] University of North Carolina Center for Heart and Vascular Care,undefined
[5] Universidade Federal de Ciências da Saúde de Porto Alegre,undefined
来源：
Journal of Thrombosis and Thrombolysis | 2011年 / 31卷
关键词：
Heart valves; Anticoagulation; Vitamin K antagonist; Warfarin; Guidelines;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with prosthetic heart valves require chronic oral anticoagulation. In this clinical scenario, physicians must be mindful of the thromboembolic and bleeding risks related to chronic anticoagulant therapy. Currently, only vitamin K antagonists are approved for this indication. This paper reviews the main heart valve guidelines focusing on the use of oral anticoagulation in these patients.
引用
收藏
页码：514 / 522
页数：8
相关论文
共 170 条
[1]  
Lloyd-Jones D(2010)Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association Circulation 121 948-954
[2]  
Adams RJ(2010)Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery N Engl J Med 363 1597-1607
[3]  
Brown TM(1942)The anticoagulants heparin and the dicoumarin 3,3′-methylene-bis-(4-hydroxycoumarin) Bull N Y Acad Med 18 433-458
[4]  
Leon MB(2008)Comparison of quality and hemorragic risk of oral anticoagulant therapy using acenocoumarol versus warfarin Med Clin (Barc) 131 96-97
[5]  
Smith CR(2009)Quality of oral anticoagulant therapy in patients who perform self management: warfarin versus phenprocoumon J Thromb Thrombolysis 28 276-281
[6]  
Mack M(2003)Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon Thromb Haemost 90 260-266
[7]  
Prandoni A(2010)Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic Arq Bras Cardiol 94 41-45
[8]  
Oliva Berini E(2003)Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study J Am Coll Cardiol 41 1445-1451
[9]  
Galan Alvarez P(2005)Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med 352 2285-2293
[10]  
Pacheco Onrubia AM(2008)Genetic determinants of response to warfarin during initial anticoagulation N Engl J Med 358 999-1008
12345678910